Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.

Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, Liu Y, Dacic S, Siegfried JM, Dahlberg SE, Schiller JH, Belinsky SA.

Oncogene. 2012 Sep 13;31(37):4107-16. doi: 10.1038/onc.2011.577. Epub 2011 Dec 12.

2.

SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen.

Shen J, Wei J, Wang H, Yang Y, Yue G, Wang L, Yu L, Xie L, Sun X, Bian X, Zou Z, Qian X, Guan W, Liu B.

PLoS One. 2013 Oct 4;8(10):e75564. doi: 10.1371/journal.pone.0075564. eCollection 2013.

3.

Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer.

Wang L, Xie L, Wang J, Shen J, Liu B.

BMC Gastroenterol. 2013 Dec 23;13:173. doi: 10.1186/1471-230X-13-173.

4.

Determinants of CPT-11 and SN-38 activities in human lung cancer cells.

van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, Jansen WJ, Pinedo HM, Boven E, Giaccone G.

Br J Cancer. 1998 Jun;77(12):2171-6.

5.

An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.

de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique.

Clin Cancer Res. 2012 May 15;18(10):2976-86. doi: 10.1158/1078-0432.CCR-11-2797. Epub 2012 Mar 20.

6.

Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.

Loprevite M, Favoni RE, de Cupis A, Pirani P, Merlo F, Grossi F, Ardizzoni A.

Int J Oncol. 1999 Oct;15(4):787-92.

PMID:
10493963
7.

IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.

Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguán-García C, Cejas P, López-Ríos F, Paz-Ares L, de CastroCarpeño J, Nistal M, Belda-Iniesta C, Perona R.

Oncogene. 2010 Mar 18;29(11):1681-90. doi: 10.1038/onc.2009.454. Epub 2009 Dec 21.

PMID:
20023704
8.

ISG15 as a novel tumor biomarker for drug sensitivity.

Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL, Giovanella BC, Liu LF.

Mol Cancer Ther. 2008 Jun;7(6):1430-9. doi: 10.1158/1535-7163.MCT-07-2345.

9.

[Correlation between the methylation of SULF2 and WRN promoter and chemosensitivity to irinotecan in gastric cancer].

Wang L, Shen J, Meng LJ, Fan WF, Wang J, Liu BR.

Zhonghua Zhong Liu Za Zhi. 2013 Jun;35(6):418-22. Chinese.

PMID:
24119900
10.

Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.

J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.

11.

SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.

Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H.

PLoS One. 2016 Feb 16;11(2):e0148911. doi: 10.1371/journal.pone.0148911. eCollection 2016.

12.

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.

Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF.

Oncol Rep. 2013 May;29(5):1975-82. doi: 10.3892/or.2013.2298. Epub 2013 Feb 21.

PMID:
23440266
13.

New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.

Huang CH, Treat J.

Oncology. 2001;61 Suppl 1:14-24. Review.

PMID:
11598410
14.

Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.

Devy J, Wargnier R, Pluot M, Nabiev I, Sukhanova A.

Anticancer Res. 2004 May-Jun;24(3a):1745-51.

15.

Antitumor activity of XR5944, a novel and potent topoisomerase poison.

Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Kofler B, Okiji S, Baguley BC, Denny WA, Charlton PA.

Anticancer Drugs. 2001 Apr;12(4):359-67.

PMID:
11335793
16.

p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.

Fukuoka K, Adachi J, Nishio K, Arioka H, Kurokawa H, Fukumoto H, Ishida T, Nomoto T, Yokote H, Tomonari A, Narita N, Yokota J, Saijo N.

Jpn J Cancer Res. 1997 Oct;88(10):1009-16.

PMID:
9414664
17.
19.

MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.

Chattopadhyay S, Machado-Pinilla R, Manguan-García C, Belda-Iniesta C, Moratilla C, Cejas P, Fresno-Vara JA, de Castro-Carpeño J, Casado E, Nistal M, Gonzalez-Barón M, Perona R.

Oncogene. 2006 Jun 1;25(23):3335-45. Epub 2006 Feb 6.

PMID:
16462770
20.

Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.

Zhao M, Gjerset RA.

PLoS One. 2015 Aug 6;10(8):e0134929. doi: 10.1371/journal.pone.0134929. eCollection 2015.

Supplemental Content

Support Center